Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions

Current Neurology and Neuroscience Reports

Volumn 2, Issue 3, 2002, Pages 216-224

  Kraemer, Dale F ^a   Fortin, David ^a   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cytosine Deaminase; Historic Control Patient; Increase Dose Intensity; Malignant Brain Tumor; Stem Cell Rescue

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN TUMOR; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METABOLISM; METHODOLOGY; OSMOSIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OSMOSIS; PATIENT SELECTION;

EID: 0036582336     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-002-0080-8     Document Type: Article

References (79)

1. DeAngelis LM: Medical progress: brain tumors. N Engl J Med 2001, 344:114–123. Reviews the best therapy (among surgery, radiation, and chemotherapy) for various types of malignant brain tumors. DOI: 10.1056/NEJM200101113440207
2. Doolittle ND, Muldoon LL, Brummett RE, et al.: Delayed sodium thiosulfate as an otoprotectant agent against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001, 7:493–500. Provides an example of chemoprotection (using sodium thiosulfate) against ototoxicity following cisplatin chemotherapy for malignant brain tumors.
3. McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51–61. DOI: 10.1097/00006123-200001000-00010
4. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083–1100. DOI: 10.1097/00006123-199805000-00082
5. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998, 58:5396–5405.
6. Fortin D, Neuwelt EA: Therapeutic manipulation of the blood brain-barrier. Neurology Medlink, Arbor. 2002.
7. Hryniuk WM, Pater JL: Implications of dose intensity for cancer chemotherapy. Semin Oncol 1987, 14:43–44.
8. Doolittle ND, Anderson CP, Bleyer WA, et al., for the Blood-Brain Barrier Disruption Consortium: Importance of dose intensity in neuro-oncology clinical trials: summary of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology 2001, 3:46–54. DOI: 10.1215/15228517-3-1-46
9. Schabel FMJr, Griswold DPJr, Corbett TH, Laster WRJr: Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984, 54:1160–1167. DOI: 10.1002/1097-0142(19840915)54:1+<1160::AID-CNCR2820541312>3.0.CO;2-P
10. Seeger RC, Reynolds CP: Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplant. Pediatr Clin North Am 1991, 38:393–424.
11. Ioannidis JP, Schmid CH, Lau J: Meta-analysis in hematology and oncology. Hematol Oncol Clin North Am 2000, 14:973–991. DOI: 10.1016/S0889-8588(05)70322-1
12. Stadtmauer EA, O’Neill A, Goldstein L, et al.: Conventionaldose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000, 342:1069–1076. DOI: 10.1056/NEJM200004133421501
13. Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991, 9:1050–1058.
14. Finlay JL, August C, Packer R, et al.: High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neuro-Oncol 1990, 9:239–248. DOI: 10.1007/BF02341155
15. Kalifa C, Hartmann O, Demeocq F, et al.: High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992, 9:227–233.
16. Mahoney DH Jr, Strother D, Camitta B, et al.: High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996, 14:382–388.
17. Tada T, Takizawa T, Nakazato F, et al.: Treatment of intracranial nongerminous germ-cell tumors by high dose chemotherapy and autologous stem-cell rescue. J Neuro-Oncol 1999, 44:71–76. DOI: 10.1023/A:1006395719917
18. Graham ML, Herndon JE II, Casey JR, et al.: High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997, 15:1814–1823.
19. Mason WP, Grovas A, Halpern S, et al.: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998, 16:210–221.
20. Cairncross G, Swinnen L, Bayer R, et al.: Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-Oncology 2000, 2:114–119. A multi-institutional trial of dose-intense chemotherapy in recurrent aggressive oligodendroglioma, but with substantial mortality. However, efficacy increased and toxicity decreased in newly diagnosed patients. DOI: 10.1215/15228517-2-2-114
21. Abrey LE, Paleologos N, Rosenfeld S, et al.: Intensive PCV chemotherapy followed by high dose thiotepa with autologous stem cell rescue (ASCR) for patients with newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology 2001, 3:354. A multi-institutional trial of dose-intense chemotherapy in recurrent aggressive oligodendroglioma, but with substantial mortality. However, efficacy increased and toxicity decreased in newly diagnosed patients.
22. Finlay JL, Goldman S, Wong MC, et al.: Pilot study of highdose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children’s Cancer Group. J Clin Oncol 1996, 14:2495–2503.
23. Doolittle ND, Miner ME, Hall WA, et al.: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000, 88:637–647. Demonstrates efficacy and safety of blood-brain barrier disruption protocols for the treatment of malignant brain tumors when implemented across multiple centers. DOI: 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y
24. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA: Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurgery 2001, 48:1033–1041. Illustrates the use of time-dependent covariate analyses for demonstration of a positive association between number of treatments (disruptions) and longer survival times. DOI: 10.1097/00006123-200105000-00013
25. Bobo RH, Laske DW, Akbasak A, et al.: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91:2076–2080. DOI: 10.1073/pnas.91.6.2076
26. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matte during interstitial drug infusion. J Neurosurgery 1995, 82:1021–1029.
27. Groothuis DR, Wards S, Itskovich AC: Comparison of Dsucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurgery 1999, 90:321–331. Compares different routes of delivery to the central nervous system with particular emphasis on convection-enhanced delivery.
28. Kaiser MG, Parsa AT, Fine RL, et al.: Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000, 47:1391–1398. DOI: 10.1097/00006123-200012000-00026
29. Bruce JN, Falavigna A, Johnson JP, et al.: Intracerebral clysis in a rat glioma model. Neurosurgery 2000, 46:683–691. DOI: 10.1097/00006123-200003000-00031
30. Cunningham J, Oiwa Y, Nagy D, et al.: Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Tranplant 2000, 9:585–594.
31. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology 2000, 2:45–59. DOI: 10.1215/15228517-2-1-45
32. Mardor Y, Roth Y, Lidar Z, et al.: Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001, 61:4971–4973.
33. Muldoon LL, Nilaver G, Kroll RA, et al.: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol 1995, 147:1840–1851.
34. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996, 38:746–752. DOI: 10.1097/00006123-199604000-00024
35. Bartus RT, Snodgrass P, Marsh J, et al.: Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. J Pharmacol Exper Therapeut 2000, 293:903–911. Describes a bradykinin analogue that preferentially opens the blood tumor barrier.
36. Brem H, Ewend MG, Piantadosi S, et al.: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neuro-Oncol 1995, 26:111–123. DOI: 10.1007/BF01060217
37. Brem H, Gabikian P: Biodegradable polymer implants to treat brain tumors. J Controlled Release 2001, 74:63–67. Reviews biodegradable polymers that release chemotherapy from the walls of the surgical tumor cavity. DOI: 10.1016/S0168-3659(01)00311-X
38. Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000, 46:704–709. DOI: 10.1097/00006123-200003000-00034
39. Boviatsis EJ, Chase M, Wei MX, et al.: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Human Gene Ther 1994, 5:183–191.
40. Breakefield XO, DeLuca NA: Herpes simplex virus for gene delivery to neurons. New Biologist 1991, 3:203–218.
41. Davidson BL, Doran SE, Shewach DS, et al.: Expression of Escherichia coli —Galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exper Neurol 1994, 125:258–267. DOI: 10.1006/exnr.1994.1028
42. Nilaver G, Muldoon LL, Kroll RA, et al.: Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci U S A 1995, 92:9829–9833. DOI: 10.1073/pnas.92.21.9829
43. Boviatsis EJ, Park JS, Sena-Esteves M, et al.: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994, 54:5745–5741.
44. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994, 91:3054–3057. DOI: 10.1073/pnas.91.8.3054
45. Markert JM, Malick A, Coen DM, Martuza RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993, 32:597–603. DOI: 10.1097/00006123-199304000-00016
46. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854–856. DOI: 10.1126/science.1851332
47. Laske DW, Ilercil O, Abbasak A, Youle RJ, Oldfield EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994, 80:520–526.
48. Bartlett JS, Samulski RJ, McCown TJ: Selective and rapid uptake of adeno-associated virus type 2 in brain. Human Gene Ther 1998, 9:1181–1186.
49. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ: A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet 1993, 3:219–223. DOI: 10.1038/ng0393-219
50. Eck SL, Alavi JB, Alavi A, et al.: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Human Gene Ther 1996, 7:1465–1482.
51. Ram Z, Culver KW, Oshiro EM, et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997, 3:1354–1361. DOI: 10.1038/nm1297-1354
52. Silbergeld DL, Chicoine MR: Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997, 86:525–531. DOI: 10.3171/jns.1997.86.3.0525
53. Waxman DJ, Chen L, Hecht JE, Jounaidi Y: Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev 1999, 31:503–522. DOI: 10.1081/DMR-100101933
54. Jounaidi Y, Waxman DJ: Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 2001, 61:4437–4444. Gene therapy delivered to tumor can activate cyclophosphamide.
55. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992, 89:33–37. DOI: 10.1073/pnas.89.1.33
56. Ichikawa T, Tamiya T, Adachi Y, et al.: In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 2000, 7:74–82. DOI: 10.1038/sj.cgt.7700086
57. Erbs P, Regulier E, Kintz J, et al.: In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000, 60:3813–3822.
58. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A: Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Human Gene Ther 1999, 10:1993–2003. DOI: 10.1089/10430349950017356
59. Stegman LD, Rehemtulla A, Hamstra DA, et al.: Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 2000, 7:1005–1010. DOI: 10.1038/sj.gt.3301199
60. Kievit E, Nyati MK, Ng E, et al.: Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000, 60:6649–6655.
61. Stackhouse MA, Pederson LC, Grizzle WE, et al.: Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther 2000, 7:1019–1026. DOI: 10.1038/sj.gt.3301196
62. Lambin P, Nuyts S, Landuyt W, et al.: The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int J Radiat Biol 2000, 76:285–293. DOI: 10.1080/095530000138628
63. Hanna NN, Mauceri HJ, Wayne JD, et al.: Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997, 57:4205–4209.
64. Pederson LC, Buchsbaum DJ, Vickers SM, et al.: Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997, 57:4325–4332.
65. Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V: Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Physics 1999, 43:107–114.
66. Barth RF, Yang W, Bartus RT, Moeschberger ML, Goodman JH: Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7). Neurosurgery 1999, 44:351–359. DOI: 10.1097/00006123-199902000-00062
67. Rosenthal DI, Nurenberg P, Becerra CR, et al.: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999, 5:739–745. Gadolinium texaphyrin sensitizes tumors to radiation and can be imaged by magnetic resonance.
68. Neuwelt EA, Brummett RE, Doolittle ND, et al.: First evidence of otoprotection against carboplatin-induced hearing loss with a two compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 1998, 286:77–84.
69. Doolittle ND, Tyson RM, Lacy C, et al.: Potential role of delayed high-dose sodium thiosulfate as protectant against carboplatin-based thrombocytopenia in patients with malignant brain tumors. Neuro-Oncology 2001, 3:357. A preliminary evaluation of potential for protection of bone marrow from toxicity to carboplatin-based chemotherapy. DOI: 10.1215/15228517-3-1-46
70. Doolittle ND, Abrey LE, Ferrari N, et al.: Targeted delivery in primary and metastatic brain tumors: enhanced delivery versus neurotoxicity. Clin Cancer Res 2002, in press. Discusses increased dose intensity in the treatment of malignant brain tumors.
71. Xu Y, Hansen WK, Rosenquist TA, et al.: Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N’-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications. J Pharmacol Exper Therapeut 2001, 296:825–831.
72. Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350–1354. DOI: 10.1056/NEJM200011093431901
73. Friedman HS, Kokkinakis DM, Pluda J, et al.: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998, 16:3570–3575.
74. Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE: Contribution of glutathione and glutathiuone-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer 1991, 49:688–695. DOI: 10.1002/ijc.2910490511
75. Anderson CP, Tsai JM, Meek WE, et al.: Depletion of glutathione by buthione sulfoximine is cytotoxic for human neuroblastoma cells lines via apoptosis. Exper Cell Res 1999, 246:183–192. Lowering tumor glutathione sensitized the tumor to alkylating chemotherapy. DOI: 10.1006/excr.1998.4303
76. Curran WJ, Scott CB, Horton J, et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704–710. DOI: 10.1093/jnci/85.9.704
77. Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neuro-Oncology 1999, 227–231. A systematic review of studies of aggressive surgical resection for high-grade astrocytomas that concludes that the evidence is limited due to lack of clinical trial data and potential biases and uncontrolled confounding variables.
78. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurgery 2001, 95:735–745. Systematic review of the association of extent of resection of low-grade gliomas on clinical outcomes. Due to lack of randomization, control of confounders is essential in analysis of nonrandomized trials.
79. Laws ERJr: Resection for low-grade gliomas [editorial]. J Neurosurgery 2001, 95:731–732. Supports notion that due to lack of randomization, control of confounders is essential in analysis of nonrandomized trials. DOI: 10.3171/jns.2001.95.5.0731